Cidara Therapeutics Statistics
Total Valuation
CDTX has a market cap or net worth of $313.42 million. The enterprise value is $146.45 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CDTX has 12.97 million shares outstanding. The number of shares has increased by 93.71% in one year.
| Current Share Class | 12.97M |
| Shares Outstanding | 12.97M |
| Shares Change (YoY) | +93.71% |
| Shares Change (QoQ) | +45.74% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 23.13% |
| Float | 4.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,032.86 |
| Forward PS | n/a |
| PB Ratio | 2.07 |
| P/TBV Ratio | 2.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 484.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.87 |
| Quick Ratio | 3.48 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -299.58% and return on invested capital (ROIC) is -102.83%.
| Return on Equity (ROE) | -299.58% |
| Return on Assets (ROA) | -55.20% |
| Return on Invested Capital (ROIC) | -102.83% |
| Return on Capital Employed (ROCE) | -75.53% |
| Revenue Per Employee | $7,947 |
| Profits Per Employee | -$4.82M |
| Employee Count | 38 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.80% in the last 52 weeks. The beta is 0.80, so CDTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +93.80% |
| 50-Day Moving Average | 21.01 |
| 200-Day Moving Average | 18.42 |
| Relative Strength Index (RSI) | 57.34 |
| Average Volume (20 Days) | 178,231 |
Short Selling Information
The latest short interest is 445,327, so 3.43% of the outstanding shares have been sold short.
| Short Interest | 445,327 |
| Short Previous Month | 452,539 |
| Short % of Shares Out | 3.43% |
| Short % of Float | 10.80% |
| Short Ratio (days to cover) | 4.42 |
Income Statement
In the last 12 months, CDTX had revenue of $302,000 and -$182.98 million in losses. Loss per share was -$20.89.
| Revenue | 302,000 |
| Gross Profit | -71.80M |
| Operating Income | -107.95M |
| Pretax Income | -36.02M |
| Net Income | -182.98M |
| EBITDA | -107.79M |
| EBIT | -107.95M |
| Loss Per Share | -$20.89 |
Full Income StatementBalance Sheet
The company has $168.15 million in cash and $2.67 million in debt, giving a net cash position of $165.48 million or $12.76 per share.
| Cash & Cash Equivalents | 168.15M |
| Total Debt | 2.67M |
| Net Cash | 165.48M |
| Net Cash Per Share | $12.76 |
| Equity (Book Value) | 141.68M |
| Book Value Per Share | 11.60 |
| Working Capital | 140.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$191.84 million and capital expenditures -$106,000, giving a free cash flow of -$191.95 million.
| Operating Cash Flow | -191.84M |
| Capital Expenditures | -106,000 |
| Free Cash Flow | -191.95M |
| FCF Per Share | -$14.80 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -35,743.71% |
| Pretax Margin | -61,454.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -93.71% |
| Shareholder Yield | -93.71% |
| Earnings Yield | -58.66% |
| FCF Yield | -61.54% |
Analyst Forecast
The average price target for CDTX is $41.33, which is 71.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.33 |
| Price Target Difference | 71.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 163.04% |
| EPS Growth Forecast (5Y) | -49.60% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 24, 2024. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Apr 24, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
CDTX has an Altman Z-Score of -4.05 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.05 |
| Piotroski F-Score | 1 |